Ftse Mib
34.660,38
-0,50%
DAX
18.557,27
-0,48%
S&P 500
5.346,99
-0,11%
NASDAQ
17.133,13
-0,23%
Bitcoin
69.352,18
0,03%
Registration Strip Icon for discussion Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ NovoCure Ltd (NVCR) NovoCure Ltd (NVCR) Notizie

NovoCure Ltd

NVCR
21,50
-0,65 (-2,93%)
08 Giu 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
07/6/202400:37EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/6/202400:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/6/202423:43EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/6/202414:00BWMETIS Phase 3 Clinical Trial Met Primary Endpoint..
24/5/202415:06BWTIGER-Studie berichtet über neue Überlebensergebnisse der..
23/5/202423:05BWTIGER Study Reports New TTFields Therapy Survival Results..
20/5/202414:01EDGAR2Form 8-K - Current report
02/5/202413:01BWNovocure Secures New $400 Million Multi-Tranche Non-Dilutive..
02/5/202413:00BWNovocure Reports First Quarter 2024 Financial Results
24/4/202416:45BWResults of Novocure’s METIS Phase 3 Clinical Trial for..
05/4/202413:00BWNovocure Announces 20 Presentations On Tumor Treating..
01/4/202413:00BWNovocure to Report First Quarter 2024 Financial Results
29/3/202401:07BWMETIS第3相臨床試験で主要評価項目を達成、非小細胞肺がんからの脳転移患者における頭蓋内進行までの期間を統計学的に有意に延長
28/3/202418:51BWKlinische Phase-3-Studie METIS erreicht primären Endpunkt..
28/3/202418:50BWL’essai clinique de phase 3 METIS a atteint son critère..
27/3/202412:00BWMETIS Phase 3 Clinical Trial Met Primary Endpoint,..
11/3/202412:00BWINNOVATE-3 Late Breaking Abstract Selected as a Best Oral..
05/3/202422:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202400:39EDGAR2Form 144 - Report of proposed sale of securities
04/3/202423:56EDGAR2Form 144 - Report of proposed sale of securities
01/3/202423:06EDGAR2Form 144 - Report of proposed sale of securities
01/3/202423:01EDGAR2Form 144 - Report of proposed sale of securities
29/2/202422:43EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/2/202422:38EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/2/202422:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/2/202422:33EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/2/202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/2/202413:11EDGAR2Form S-8 - Securities to be offered to employees in employee..
22/2/202413:06EDGAR2Form 8-K - Current report
22/2/202413:05EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
22/2/202413:00BWNovocure Reports Fourth Quarter and Full Year 2023 Financial..
18/1/202417:10DJNNovocure Shares Rise 17% After FDA Accepts Pre-Market..
18/1/202413:01EDGAR2Form 8-K - Current report
18/1/202413:00BWNovocure Announces FDA Acceptance of the PMA Application for..
12/1/202422:57EDGAR2Form 3 - Initial statement of beneficial ownership of..
09/1/202413:00EDGAR2Form 8-K - Current report
09/1/202413:00BWNovocure Announces Last Patient Enrolled in Phase 3 TRIDENT..
08/1/202413:10EDGAR2Form 8-K - Current report
08/1/202413:00BWNovocure Announces Preliminary Full Year and Fourth Quarter..
04/1/202422:10EDGAR2Form 8-K - Current report
04/1/202422:05BWNovocure Appoints Dr. Nicolas Leupin as Chief Medical..
27/12/202313:00BWNovocure to Participate in 42nd Annual J.P. Morgan..
28/11/202313:30EDGAR2Form 8-K - Current report
28/11/202313:30BWNovocure Announces Portfolio Prioritization and Strategic..
21/11/202313:00BWNovocure to Participate in 35th Annual Piper Sandler..
10/11/202314:00BWNovocure Announces Presentations on Tumor Treating Fields..
08/11/202322:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/11/202321:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/11/202321:20EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/10/202313:03EDGAR2Form 8-K - Current report
Apertura: 21,43 Min: 21,20 Max: 21,8022
Chiusura: 22,15

La tua Cronologia

NASDAQ
NVCR
NovoCure
ASX
PLAR
BIT
UB7RU6
Unicredit Bank
USOTC
ABLT
American Biltrite (PK)
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network